|
Sep 16
|
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
|
|
Aug 1
|
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
|
|
Jul 31
|
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time
|
|
Jul 29
|
PDS Biotech to Participate at BTIG Virtual Biotechnology Conference
|
|
May 15
|
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
|
|
May 9
|
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
|
|
May 9
|
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
|
|
May 7
|
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
|
|
May 3
|
PDS Biotechnology Announces Details of Virtual KOL Event
|
|
May 2
|
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
|
|
Apr 23
|
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
|
|
Mar 30
|
PDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who hold 59% were hit as were institutions
|
|
Mar 28
|
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript
|
|
Mar 28
|
Q4 2023 PDS Biotechnology Corp Earnings Call
|
|
Mar 27
|
PDS Biotechnology Corp (PDSB) Reports Full Year 2023 Financial Results and Clinical Strategy Update
|
|
Mar 27
|
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
|
|
Mar 20
|
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
|
|
Mar 13
|
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
|
|
Mar 13
|
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
|
|
Jan 16
|
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
|